University of Virginia

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Virginia sits in the top decile of US sponsors by registered trial count (#78 of 15,742 sponsors by registered trial count).

449 total trials 101 currently recruiting 281 completed early-phase tilt top decile by trial count

University of Virginia: 449 sponsored US clinical trials, 101 recruiting.

University of Virginia sponsors 449 registered US clinical trials on ClinicalTrials.gov, 101 of them currently recruiting, and 281 completed. 40 of these trials are in Phase 3-4 (later-stage) and 109 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 1 Diabetes Mellitus, with 9 trials.

Top-decile sponsor footprint

University of Virginia ranks in the top decile of sponsors by registered trial count (#78 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 61/100

281 of 317 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

449 total, page 4 of 9

TERMINATED NA

Ketogenic Dietary Patterns in Young Adults and Kidney Health

NCT05350657

TERMINATED NA

High Fat Meal and Postprandial TG Levels With and Without Exercise Intervention

NCT05291767

COMPLETED NA

Effects of Acute Exercise Intensity on Cerebral Blood Flow and Cognitive Function in Older Adults

NCT05131217

COMPLETED NA

Optimizing Efficiency and Impact of Digital Health Interventions for Caregivers

NCT04986904

COMPLETED NA

Measurement and Modification of Threat Interpretation Bias in Neurodegenerative Movement Disorders (Aims 2 & 3)

NCT05126862

COMPLETED NA

Establishing the Effectiveness of Publicly Available Smoking Cessation Resource

NCT05055778

COMPLETED Phase 1

Effects of Inorganic Nitrate and Intensity of Exercise on Cardiovascular Health in Post-Menopausal Females

NCT05221905

COMPLETED Phase 4

Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients

NCT04376762

TERMINATED NA

Exercise Preconditioning in Ovarian Cancer

NCT05029154

COMPLETED NA

Mobile Apps to Reduce Distress in Breast Cancer Survivors Using an Adaptive Design

NCT04583891

COMPLETED NA

QuitAid Pilot Feasibility Trial

NCT05649241

COMPLETED

Fetal Cardiac Function Parameters and HbA1c As Screening for Gestational Diabetes Mellitus

NCT05019508

COMPLETED Phase 3

Liposomal Bupivacaine Versus Non-liposomal Bupivacaine for Total Shoulder Arthroplasty

NCT04974385

COMPLETED

Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis

NCT04642391

COMPLETED NA

iSIPsmarter: An RCT Evaluating the Efficacy of a Technology-Based Intervention to Reduce Sugary Drinks in Rural Appalachia

NCT05030753

COMPLETED NA

Behavioral Activation for Treatment of Depression in Adolescents With Autism

NCT05018169

COMPLETED NA

Adaptive Biobehavioral Control (ABC) of Automated Insulin Delivery

NCT04784637

COMPLETED NA

The Emotional, Physical and Cognitive Benefits of Purposeful Green Space Activities on Seniors

NCT04913363

COMPLETED Phase 2

Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients

NCT04920916

COMPLETED NA

Diabetes Closed-Loop Project 6 (DCLP6): Fully Automated Closed-Loop Control in Type 1 Diabetes Using Meal Anticipation

NCT04877730

COMPLETED NA

Hybrid Closed-Loop Control With Smart Prandial Insulin Dosing in Type 1 Diabetes

NCT04878120

COMPLETED

Telehealth and Meal Replacement Pilot Program for Patients With Diabetes

NCT04885621

COMPLETED

Effect of Postprandial Hyperglycemia on Vasculature in Type 1 Diabetes and Healthy Adults

NCT04730882

COMPLETED NA

A Randomized Study to Compare a Hydrogel Packing System to Standard Packing During HDR Brachytherapy for Cervical Cancer

NCT04499521

COMPLETED Phase 4

Effectiveness of Exparel TAP Block in Breast Free Flap Reconstruction

NCT04777591

COMPLETED NA

Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT

NCT04629430

COMPLETED

Glycemic Profiles And Insulin Delivery Across The Menstrual Cycle In Women With Type 1 Diabetes

NCT04665999

COMPLETED

Living Alone is Predictive of Non-home Discharge Following Elective Total Hip Arthroplasty: a Matched-pairs Cohort Analysis

NCT06462885

COMPLETED NA

Fully Automated Closed Loop Control in Adolescents With Type 1 Diabetes

NCT04545567

COMPLETED NA

PENG Block for Arthroscopic Hip Surgery

NCT04508504

COMPLETED Phase 4

Capsaicin for the Treatment of Cannabinoid Hyperemesis Syndrome

NCT04283292

COMPLETED NA

Artificial Pancreas - Adolescent Physiology & Psychology Longitudinal Evaluation

NCT04510506

COMPLETED NA

The Use of Libre to Improve Metabolic Control and Reduce Reliance on Medication

NCT04632849

COMPLETED NA

Effectiveness of Respiratory Protection During Simulated Resuscitation: a Prospective Cohort Study

NCT04591756

COMPLETED NA

Smartphone Application Smoking Cessation Study

NCT04623736

COMPLETED NA

Effects of Obesity and Intensity of Exercise on Ghrelin Levels

NCT04581980

COMPLETED NA

Web-Based Simulation Tool For Self-Management Support In Type 1 Diabetes Mellitus

NCT04439903

COMPLETED NA

The Better Sleep for Supporters With Insomnia Study

NCT04661306

COMPLETED NA

Adapting Diabetes Treatment Expert Systems to Patient in Type 1 Diabetes

NCT04443153

COMPLETED Phase 2

Is Topical CBD Effective in Treating Thumb Joint Arthritis

NCT04611347

COMPLETED

Patient Outcomes of Clinic Transition From Face to Face Encounter to Telemedicine in Cystic Fibrosis

NCT04402801

COMPLETED Phase 2

Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia

NCT04374565

COMPLETED NA

Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic

NCT04368260

COMPLETED NA

Interleukin-5 Receptor Expression in COPD

NCT03984799

COMPLETED NA

Evaluation of Accuracy of Continuous Glucose Monitoring (CGM) in Patients With End Stage Renal Disease (ESRD) on Intermittent Hemodialysis (iHD).

NCT04094064

COMPLETED NA

Gait-Training Using Wearable Sensors

NCT04270565

COMPLETED Phase 1

Inorganic Nitrate: Sex Differences in Muscle Contractile Function and Efficiency

NCT04588740

TERMINATED

Impaired Glucose Tolerance and Cognition in MS

NCT04748302

COMPLETED NA

Knee Biofeedback Rehabilitation Interface for Game-based Home Therapy for Patients With Knee Osteoarthritis

NCT04187092

COMPLETED

Feasibility of Using Contrast Enhanced Voiding Urosonography (CeVUS) During Urodynamic Studies

NCT04170413

← Previous Page 4 of 9 Next →

Phase Distribution

PhaseTrial count
Phase 1 58
Phase 2 51
Phase 3 14
Phase 4 26

What is open in the University of Virginia pipeline

101 recruiting of 449 indexed (22% open); 281 completed (63%).

Phase mix: 40 late (III/IV) vs 109 early (I/II) (early-phase heavy).

Top condition: Type 1 Diabetes Mellitus (9 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Virginia: open-pipeline peers nationwide

Peers matched on 449 registered trials and 22% open enrollment, not the therapeutic-area sidebar.

University of Virginia sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 5%10%15%20%25% Total trials Recruiting share University of VirginiaMedical College of WisconsinAlliance for Clinical Trials in OncologyBoston Children's HospitalChildren's Hospital of PhiladelphiaOhio State University Comprehensive Cancer CenterUniversity of DelawareUniversity of OklahomaALX Oncology
University of Virginia sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Virginia sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 449 trials (± recruiting share)

Sponsors near 22% open enrollment (± trial volume)

What to do with this University of Virginia page

449 registered trials is a research-attention snapshot, not an endorsement of University of Virginia or any single study.

  • 101 of University of Virginia's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Type 1 Diabetes Mellitus is the condition University of Virginia studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 1 Diabetes Mellitus trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Virginia pipeline card: 449 registered trials from official public datasets.Report a data error.